Saïd El Alaoui PhD CEO CovalAb
CovalAb has been founded in 1995 by Dr Saïd El Alaoui and Dr Vincent Thomas as a spin-off of the University of Lyon (France).
Thanks to its know-how in immunology, the CovalAb’s team comes-along and finalises every day several projects for Academic research teams and private companies.
CovalAb has then acquired an expertise in the fields of health, environment and agro-food which has awarded an international recognition of the company.
The activities are focused on the antibody engineering and more precisely on the custom services.
- Custom antibody development (polyclonal and monoclonal antibodies)
- Monoclonal antibody production
- Peptide synthesis
- Antibody purification and labelling
- Solid phase fonctionalisation (Beads, plates, ..)
- Detection kits development
- Immuno-affinity support development (Columns, beads…)
Some of novel and innovative products and activities have been developed in response to the requests of clients or as off-shoots of fundamental research projects carried out in collaboration with researchers, others, as a result of Covalab’s own research projects. These have led to (1) the filing of patent applications (2) CovalAb’s intellectual and practical participation (not simply as a supplier of reagents) in many publications and conferences organisation.
The successful completion of its own in-house research programmes now permits CovalAb to offer potential clients its recently improved know-how in custom antibody services and novel antibodies which are of valuable tools for research, diagnosis and therapeutics.Recent publications:
Sakly W, Thomas V, Quash G, El Alaoui S.
A role for tissue transglutaminase in alpha-gliadin peptide cytotoxicity.
Clin Exp Immunol. 2006 Dec;146(3):550-8
El Alaoui S, Gresti C.
Development of an immunocapture method for measuring IgA antibodies to tissue transglutaminase in the sera of patients with coeliac disease.
Clin Exp Immunol. 2006 Apr;144(1):101-9.
Thomas V, El Alaoui S, Massignon D, Clément S, Simonet F, Quash G.
Development and evaluation of a modified colorimetric solid-phase microassay for measuring the activity of cellular and plasma (Factor XIII) transglutaminases.
Biotechnol Appl Biochem. 2006 Mar;43(Pt 3):171-9
COVALAB S.A.R.L
11 avenue Albert Einstein
69100 Villeurbanne
France
phone: +33(0) 437 654 230
fax: +33(0) 437 289 416